Abstract HIV-positive patients may be effectively treated with highly active antiretroviral therapy and such a strategy is associated with striking immune recovery and viral load reduction to very low levels. Despite undeniable results, the central nervous system (CNS) is commonly affected during the course of HIV infection, with neurocognitive disorders being as prevalent as 20-50 % of treated subjects. This review discusses the pathophysiology of CNS infection by HIV and the barriers to efficacious control of such a mechanism, including the available data on compartmental drug penetration and on pharmacokinetic/pharmacodynamic relationships. In the reviewed articles, a high variability in drug transfer to the CNS is highlighted with several mechanisms as well as methodological issues potentially influencing the observed results. Nevirapine and zidovudine showed the highest cerebrospinal fluid (CSF) to plasma ratios, although target concentrations are currently unknown for the CNS. The use of the composite CSF concentration effectiveness score has been associated with better virological outcomes (lower HIV RNA) but has been inconsistently associated with neurocognitive outcomes. These findings support the CNS effectiveness of commonly used highly antiretroviral therapies. The use of antiretroviral drugs with increased CSF penetration and/or effectiveness in treating or preventing neurocognitive disorders however needs to be assessed in well-designed prospective studies.
Introduction
HIV enters the central nervous system (CNS) early in the natural history of the disease with cerebrospinal fluid (CSF) HIV RNA recovered as early as 8 days after infection [1] . The presence of viral replication (in perivascular macrophages and microglia and, although restricted, in astrocytes) is eventually associated with neuronal damage due to persistent immune activation and cytokines production: the clinical endpoint of untreated CNS HIV infection is the appearance of HIV-associated dementia (HAD) [2, 3] . With the introduction of highly active antiretroviral therapy (HAART), the incidence of dementia significantly declined; nevertheless, cognitive impairment [asymptomatic and moderate according to the impact on everyday life and globally defined as HIV-associated neurocognitive disorders (HAND)] remains highly prevalent [4] . Although several authors highlight the impact of traditional risk factors (age, drug and alcohol abuse, previous head injuries, cardiovascular risk abnormalities, opportunistic infections) [5] on neurocognitive impairment in HIVpositive subjects, the role of neuro-effective HAART is crucial: it is significantly associated with CSF viral control but inconsistently with the prevention and treatment of HAND.
This review analyses the pharmacokinetics and pharmacodynamics of antiretroviral drugs in the CNS, considering the effect on both compartmental viral replication and neurocognitive impairment.
HIV-positive patients, we focused on pharmacokinetic and pharmacodynamic data. The aim was to include all studies containing pharmacokinetic data pertaining to and using the following search terms: [(HIV AND (central nervous system OR cerebrospinal fluid) AND (pharmacokinetics OR pharmacokinetic OR pharmacodynamic OR passage)]. For the pharmacodynamic chapter the following search terms were used: [(HIV AND (CPE OR central nervous system concentration effectiveness score OR HIV RNA)]. Review articles were included for finding references and unpublished conference abstracts. Articles were not restricted based on year of publication or language. Articles identified by the PubMed search were further screened manually by review of the full article text.
Pathophysiology of Central Nervous System (CNS)
Injury by HIV
The neuropathogenesis of CNS damage is generally considered to be initiated and driven by HIV invasion and replication within the brain parenchyma; productive infection of brain perivascular macrophages and endogenous microglia and restricted infection of astrocytes have been demonstrated [6, 7] . Consequently, neuroinflammation and immune activation of resident glia (macrophages, microglia, astrocytes) have been associated with indirect neuronal injury [2] . With no antiretroviral treatment, activated microglia, infiltrating macrophages, reduced synaptic and dendritic density and neuronal loss are the neuropathological correlates of HAD [8, 9] . With the introduction of HAART, lymphocytes infiltration was markedly reduced (and limited to immunereconstitution inflammatory syndrome cases) while neuroinflammation was observed in different anatomical sites: while basal ganglia were involved in pre-HAART specimens, in post-HAART samples hippocampus and adjacent parts of entorhinal and temporal cortex were frequently involved [10, 11] . Inflammatory cytokines and chemokines [tumour necrosis factor (TNF)-a, interleukin (IL)-6, IL-10, chemokine C-C motif ligand 2 (CCL-2), C-X-C motif chemokine 10 (CXCL-10)] have been found to be abnormally elevated in HIV-positive patients and have been linked to the alteration of the blood-brain barrier (BBB): viral factors (TAT, gp120) and lipopolysaccharide have been also implicated [3] . The impairment in BBB function has a crucial impact on the pathogenesis of HAD since it facilitates the penetration of HIV-infected monocytes, thus increasing the viral biomass in the CNS [12, 13] . BBB damage may persist despite effective antiretroviral treatment and a low nadir CD4? T lymphocyte cell count has recently been identified as a predictor of such an event [14] [15] [16] . The immune cell trafficking from and toward the CNS has the potential to sustain the persistence of residual viraemia; although the exact origin of the latter is still debated [17] , it has been proven that drugs with lower diffusion into tissues [such as protease inhibitors (PIs)] have been associated with either higher residual viraemia or replication in sanctuary sites (such as lymph nodes) [18] . Furthermore, the CNS has been recognised as a site of compartmentalised viral replication, with the possible divergent evolution of HIV quasispecies [19, 20] . Approximately 10 % of patients have detectable HIV RNA in the CSF despite plasma viral control; this 'CSF escape' is usually transient and is not associated with neurological sequelae [21] . However, different resistance-associated mutations may be selected in the CSF and cases of symptomatic (and severe) CSF escape have been constantly reported in recent years [22, 23] .
The compartmental pharmacokinetic and pharmacodynamic profile of antiretrovirals may be of relevant importance both for HIV control in the CNS and for the reduction of viral biomass in reservoir sites in sight of seeking a functional cure.
HIV-Associated Neurocognitive Disorders (HAND)
A consensus research definition of HAND includes the subclassifications asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND) and HAD [24] . This categorization relies upon the execution of a full battery of neurocognitive tests (assessing at least five domains, including attention-information processing, language, abstraction-executive, complex perceptual motor skills, memory, simple motor skills or sensory perceptual skills) and upon the determination of functional status (usually selfreported). Patients presenting abnormalities in two cognitive domains [age-adjusted scores 1 standard deviation (SD) lower than the average] are diagnosed with ANI or MND (with no or mild impairment in daily living, respectively); significant deficit in two cognitive domains (with scores lower than 2 SD) and impairment in everyday living are the diagnostic criteria for HAD. Considerable uncertainty is still undeniable in the diagnosis, determinants, prognostic factors and treatment of HAND, although HAART has been associated with significant improvement in symptoms and CSF markers of immune activation and neuronal damage in patients with HAD [4] . One of the key questions is whether the diagnosis of ANI has any relevance in the course of HIV infection: recent data suggest that patients with ANI may progress to MND and that they have a significant impairment in performance-based tests (potentially affecting adherence to medications) [25, 26] . The uncertainty in this area is enhanced by the diagnostic criteria that, to some extent, may overestimate the prevalence of asymptomatic and mild forms of neurocognitive impairment.
Furthermore, several authors highlight the high prevalence of other risk factors for neurocognitive decline such as increasing age, high cardio-and cerebrovascular risk, the often under-diagnosed presence of psychiatric illnesses, the use of psychotropic substances and the prevalence of chronic hepatitis [and specifically hepatitis C virus (HCV)] [5, 27] . The challenge of studying HAND is having an adequate well-matched control group in which all of these confounding factors may be accounted for [28] . Nevertheless, some HIV-associated (CD4 cell count at nadir below 200/mm 3 , plasmatic or CSF HIV replication, cellassociated HIV DNA) and some other risk factors (age above 50 years, HCV infection, metabolic and glucose abnormalities, cardiovascular risk) have been identified and they may help in selecting patients for accurate neurocognitive screening and follow-up. Finally, a therapeutic approach is not clearly defined since controlling HIV replication may be necessary but not sufficient: neither higher CNS-penetrating combined antiretroviral therapy nor adjuvant treatments have so far proven to be effective in preventing and reversing HAND [29] .
Mechanisms of Drug Passage to the CNS
To be efficacious, drugs must reach adequate concentrations at the site of action: in the case of CNS infection by HIV, the targets are macrophages, microglia and astrocytes within the brain parenchyma. After intestinal absorption, orally administered antiretrovirals (the vast majority of available drugs, with the exception of intravenous zidovudine and subcutaneous enfuvirtide) are transported by plasma proteins in the bloodstream and distributed to organs and tissues. The CNS is reached by a considerable blood flow (approximately 14 % of cardiac output) but two anatomical barriers can be found that prevent the free passage of drugs into the brain: the BBB and the blood-CSF barrier (BCB). The first one is characterised by endothelial cells connected by tight junctions and by the presence of astrocytic end feet: several substances are restricted from crossing the BBB [30] . Nevertheless, tight junctions are absent in some areas of the brain (hypothalamus, area postrema, subfornical organ) and direct diffusion is possible. Several mechanisms have been identified for crossing the BBB and they affect each compound's ability to reach the brain tissue: paracellular aqueous pathway, transcellular lipophilic pathway, transport proteins, receptor-mediated transcytosis and adsorptive transcytosis. Therefore, both patients' and drugs' characteristics influence antiretrovirals' passage into the CNS.
The study of the pharmacokinetics of antiretrovirals in the CNS has two key obstacles: the scarce data on tissue concentrations and the intracellular target of action. Obtaining brain tissue concentrations is limited in healthy patients (for obvious ethical reasons) and is associated with potential bias in sick individuals (brain biopsies are usually performed in patients with severe CNS diseases and this may impact the results of measured concentrations): data on autoptic measurements are limited and they may be influenced by the time elapsed from death to the procedure. Furthermore, brain parenchyma concentrations derive from different compartments (averaged as a single measurement per gram of tissue) and they may be influenced by preparation and analysis procedures [31] . Microdyalisis is another option for directly measuring brain extracellular concentrations (through the use of intracranial catheters): however, it is an invasive technique and the results may depend upon the characteristics of the compounds [32, 33] . CSF concentrations are easier to obtain but their reliability as markers of CNS exposure is still debated. CSF is believed to be produced by filtration from blood plasma (two-thirds) and from brain extracellular fluid (one-third), from which it is separated by one layer of ependymal cells; nevertheless, a difference in drug concentrations may be observed if CSF is withdrawn from cisterna magna or from lumbar space [34] . Several animal studies have suggested that CSF is a reliable surrogate marker for most of the studied drugs; although the variability in predicting tissue concentrations was high, it was considerably lower than plasma unbound concentrations and comparable with microdyalisis [33, 35, 36] . As an example, animal data (non-human primates) confirmed the good correlation between zidovudine CSF and brain parenchyma concentrations; [32] data for other antiretrovirals are more variable and have recently been reviewed by Eisfeld et al. [37] . Additionally, drug concentrations in brain tissue are not uniform; they may vary with the distance from the CSF, with the vascularity of brain regions, and between white and grey matter [38] . Since the perivascular areas are probably the main objective of antiretroviral therapy, this may not be relevant in the delivery of drugs to target cells [39] .
The second pitfall in the evaluation of CNS exposure is the site of action: with the exception of enfuvirtide and maraviroc, all antiretrovirals have intracellular targets. While non-nucleoside reverse transcriptase inhibitors (NNRTIs), PIs and integrase strand transfer inhibitors (ISTIs) once inside the cells are ready for exerting their activity, nucleoside reverse transcriptase inhibitors (NRTIs) need to be phosphorylated (thrice or twice) to become active and compete with endogenous nucleosides. The direct relationship between plasma and intracellular concentrations support the measurement of the former; however, no data are currently available on the concentrations reached inside CNS macrophages, microglia or astrocytes.
Patients' Characteristics and Blood-Brain Barrier Damage
Older age may affect the passage of several drugs into the CNS: reduced blood efflux, permissive BBB and altered CSF flow are some of the potential mechanisms [40] . Being atherosclerosis and cerebrovascular disease common in older HIV-positive patients this may be relevant [41, 42] . Furthermore, as a consequence of declining renal function, plasma concentrations of several antiretrovirals have been shown to increase with increasing age. The only available data suggest that while plasma concentrations of efavirenz and tenofovir are increased in older subjects, efavirenz CSF concentration have a steep increase after 60 years of age [43] . Meningeal inflammation (usually observed in acute infection, rebound encephalitis, CSF escape or with opportunistic infections) has the potential to modulate the penetration of antiretrovirals: this is mediated by blood flow, BBB impairment and pH modifications. The latter mechanism has been identified in bacterial meningitis but may be relevant for drugs very sensitive to pH, such as raltegravir [44] .
Finally, BBB impairment has been considered as a key event in the pathogenesis of AIDS dementia complex and other HIV-related neurological complications. BBB alterations were found in 2-22 % of HIV-positive asymptomatic individuals, in about 50 % of patients with AIDS and in 100 % of patients with HAD [45] [46] [47] . Furthermore, altered permeability may persist in a subset of patients (mostly those with a low CD4? T lymphocytes nadir) despite antiretroviral treatment and it has been associated with a higher prevalence of HAND [14] [15] [16] . Theoretically, a permissive barrier may allow the passage of both drugs and plasma proteins, thus increasing CSF total concentrations but reducing free drug concentrations: the net effect on antiviral efficacy is currently not known [48] . Tenofovir, emtricitabine and raltegravir CSF concentrations have been shown to be higher in the presence of altered BBB and to be directly proportional to CSF to plasma albumin ratios (CSARs) [49] [50] [51] .
Drug Characteristics
Four chemical characteristics that affect drug passage have been identified: molecular weight (the smaller the higher), lipophilicity (the higher the higher, measured as octanol water distribution coefficient, LogP), ionization (the higher the lower) and plasma protein binding (the lower the higher). Table 1 shows the molecular size, LogP and unbound plasma fractions for available antiretrovirals. NRTIs are small, poorly bound molecules with a generally high CSF to plasma ratio; tenofovir is an exception to this example since it is positively charged and thus requires active transport to cross the BBB. Molecular size and lipophilicity can be graphically plotted and an area of optimal characteristics can be drawn, as in a recent paper by Marzolini et al. [52] : drugs with a distribution coefficient (LogD, a measure of pH-dependant lipophilicity) between -1 and ?5 and with a cross-sectional area between 20 and 70 (Å 2 ) showed the highest penetration into the CSF. Protein binding has been classically identified as one of the key characteristics affecting drug distribution into organs and tissues; highly protein bound molecules have less unbound (or free) drug available for exerting the effect or being transported outside the blood stream. The effect of proteins on antiviral effect has been studied in vitro: at higher levels intracellular antiretroviral concentrations are reduced as well as their antiviral effect [53] . This seems to be confirmed in the CSF since a direct relationship between plasma unbound fraction and CSF to plasma ratios has been shown for some antiretrovirals [54] [55] [56] . Measuring unbound CSF concentrations has proven to be more challenging due to low drug and protein concentrations: CSF albumin is usually 7.8-40 mg/L in CSF and 35-55 g/L in plasma, with normal CSAR ranging from 6 to 9.5 according to age [57] . Data are available for few compounds: CSF drug concentrations were shown to be very close to plasma unbound ones [56, 58, 59] . Etravirine passage is unexpectedly peculiar: despite very low unbound plasma concentrations (approximately 0.1 %), the total etravirine CSF to plasma ratio was around 4 % [60] . However, etravirine was found to be highly protein bound in the CSF, although the authors were not able to understand the target proteins. This unexpected finding may be explained by specific binding to other plasma/CSF proteins or to the effect of concomitantly administered drugs (since etravirine is often administered with boosted PIs).
Transporters and Pharmacogenetics
Several transporting proteins have been found to be expressed at the BBB and at the BCB: p-glycoprotein (Pgp), organic anion transporter (OAT) 1, 2 and 3, breast cancer resistance protein (BCRP) and others. P-gp has been extensively studied as it mediates adenosine triphosphate (ATP)-dependant efflux of several drugs towards the bloodstream, thus potentially reducing the amount available for reaching the brain parenchyma; it has also been implicated in refractory epilepsy [61] . Positron emission tomography (PET) techniques were used to quantify (both in animal and in humans) the effect of functionally or pharmacologically inhibited P-gp: several substrates showed a huge increase in brain parenchyma diffusion [62] . Other transporters have been less extensively studied but they are expressed at the brain barriers and, for instance, PIs have been shown to be substrate of OAT1A2 [63, 64] .
The importance of understanding drug passage across BBB and BCB lies in the modulatory effects on transporters and on the possible influence of genetic polymorphisms affecting enzyme activity or expression. In non-human primates (using nelfinavir and zosiquidar, a P-gp inhibitor) P-gp blocking was associated with modest increases in CSF concentrations but extensive increments in brain concentrations [65] . Large lipophilic drugs such as PIs have strong binding affinities to drug efflux transporters expressed at the BBB and thus are prevented from entering the brain [52] . When combined, ritonavir (having the highest affinity) will occupy a large proportion of the transporter binding sites and thus slow down the efflux rate of the coadministered PI, thereby facilitating its brain entry. This was confirmed in a study comparing once-daily (800 mg with ritonavir 100 mg) with twice-daily darunavir (600 mg with ritonavir 100 mg twice daily): CSF concentrations (as expected given the lower dose) but also CSF to plasma ratios were lower, possibly because of a reduced ritonavir effect along the dosing interval [66] . Several other drugs are inhibitors or inducers of P-gp and the new pharmacoenhancer cobicistat has the same interacting potential on transporters (P-gp and BCRP) as ritonavir [67, 68] . Several genetic polymorphisms may affect the function or expression of metabolising or transporting enzymes, thus affecting drug exposure. While pharmacogenetic studies have extensively studied plasma pharmacokinetics of antiretrovirals, limited data are available on their effect on CNS exposure. Single nucleotide polymorphisms (SNPs) in cytochrome P450 (CYP) 2B6 have been associated with plasma efavirenz concentrations as well as the occurrence of neuropsychiatric symptoms and withdrawal from treatment [69, 70] . In a limited sample size study, CYP2B6 slow-metabolising children had higher CSF nevirapine concentrations than fast metabolizers [71] . In the aforementioned study on darunavir CSF concentrations, a borderline association was found between polymorphisms in the SLCO1A2 gene (encoding for OAT1A2) and CSF concentrations [66] . Finally, SNPs in the Hepatic Nuclear Factor 4 alpha (HNFalpha4, a nuclear factor implicated in the regulation of OATs) might explain some of the extreme variability observed in raltegravir CSF penetration [51] .
Plasma Concentrations
A direct correlation between plasma and CSF concentrations has been demonstrated for the majority of antiretrovirals (Table 1) . Therefore, factors affecting plasma concentrations may potentially influence CNS exposure; for instance, unboosted atazanavir (400 mg without ritonavir) is associated with very low and often undetectable CSF concentrations, as expected from the low plasma exposure observed with such a dosage [72] . Once-daily administered drugs may therefore reach lower concentrations as has been shown for darunavir/ritonavir (800/100 mg): even if no data are available, it may also be relevant for abacavir (for which all data have been derived from the twice-daily dosage) and for maraviroc (studied at 150 mg once daily with boosted PIs) [55, [73] [74] [75] [76] . Furthermore, drug-to-drug interactions reducing the plasma exposure of one antiretroviral may significantly affect CNS exposure and efficacy.
CNS Penetration of Antiretrovirals
CSF concentrations and pharmacokinetic parameters of antiretrovirals are summarised in Table 1 . Here, we briefly describe some of the key pharmacological features of those compounds, according to drug class.
Nucleoside Reverse Transcriptase Inhibitors
NRTIs are small, hydrophilic molecules, which are poorly bound to plasma proteins and reach very variable CSF exposures. NRTIs are transported by OATs that have been shown to be present at the choroid plexus (OAT1 and OAT3); the modulation of their activity (either by other drugs such as probenecid or by genetic polymorphisms in the encoding genes) may be relevant for zidovudine, stavudine, lamivudine and tenofovir passage [97] . With the exception of didanosine (whose CSF exposure has been found to be undetectable or very low), the other NRTIs have been associated with therapeutic CSF concentrations. Tenofovir is ionised at physiological pH and this limits its uptake by membrane transporters [50, 73, [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] . CSF tenofovir concentrations have been described as very low [and with no sample above a concentration of drug producing 50 % inhibition (IC 50 ) of 201 ng/mL]; previous animal data suggested a good CSF passage (through the BCB and OATs independent) but poor penetration into deep brain tissue [98] .
Non-Nucleoside Reverse Transcriptase Inhibitors
NNRTIs show different properties but are small, lipophilic, highly protein bound (with the exception of nevirapine) compounds [51, 58, 60, 71, 87, [99] [100] [101] [102] [103] . The neuropsychiatric effects in efavirenz recipients account for its passage into the CNS: nevertheless, as the IC 50 is very low (0.5-1.3 ng/mL) and close to the limit of detection of the instruments, a few studies reported poor passage into the CSF. While the data on rilpivirine (one single study) and etravirine (two reports) are still limited, high nevirapine CSF to plasma ratios have been constantly confirmed: the compound properties as well as the in vivo data suggest that nevirapine is one of the antiretrovirals with the highest CSF penetration.
Protease Inhibitors
PIs are large (with molecular weights above 500 Da), lipophilic, highly protein bound (with the exception of indinavir) compounds with CSF concentrations approximately 1 % of plasma concentrations [54, 56, 59, 72, [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] ; they have been recognised as substrates of P-gp as well as OAT1A2 and this may limit the drug accumulation into the CNS (as well as into other key tissues such as lymph nodes) [64, 116] . While tipranavir has not been studied, data from first-generation PIs were disappointing, with nelfinavir, saquinavir and amprenavir being undetectable or below the IC 50 in most patients. Indinavir CSF exposure was somehow higher, probably due to lower binding to plasma proteins: CSF concentrations were above the concentration of drug producing 95 % inhibition (IC 95 ) and it was mostly unbound (98.6 %). Comparison of the three commonly prescribed PIs (atazanavir, lopinavir and darunavir) favours lopinavir and darunavir since most of atazanavir concentrations were very low or undetectable [117] .
Entry Inhibitors (Fusion Inhibitors and CCR5
Antagonists)
Enfuvirtide is a synthetic 36 amino acid oligopeptide (interacting with viral gp41) with a very large molecular weight: a single study confirmed that CSF concentrations were below the limit of quantification (25 ng/mL), while a case report of emerging enfuvirtide-resistant CSF (and then plasma) viruses reported a CSF concentration of 55 ng/mL [118, 119] . Maraviroc is a small, lipophilic, intermediately proteinbound compound that targets the human co-receptor C-C chemokine receptor type 5 (CCR5) and that is effective in preventing entry of R5-tropic HIV viruses into target cells. It is a substrate of both CYP3A4 and P-gp and drug-drug interactions, potentially affecting CSF penetration, have been reported. The available data have been obtained with twice-daily dosages (150 mg with PIs, 300 mg with NRTIs and nevirapine, and 600 mg with efavirenz or etravirine): CSF concentrations were detectable, 2-3 % of plasma concentrations and in the range of concentrations producing 90 % of maximum effect (EC 90 ) (0.06-10.7 ng/mL) [55, [74] [75] [76] .
Integrase Strand Transfer Inhibitors
Integrase inhibitors are the latest antiretroviral drug class and are somehow heterogeneous: while they are small, highly protein-bound molecules, their lipophilicity varies considerably (raltegravir is hydrophilic while elvitegravir is lipophilic). So far no data have been released on elvitegravir CSF exposure, while a single unpublished study reported low CSF to plasma ratios (0.4 %) for dolutegravir but CSF concentrations above IC 50 in all samples [122] . Raltegravir pharmacokinetics have peculiar characteristics: very wide inter-and intra-individual variability and an unclear pharmacokinetic/pharmacodynamic relationship [49, 51, 123] . Even if pH-dependant absorption may explain much plasma variability, raltegravir CSF to plasma ratios have been described as varying from 3 to 20 %.
Pharmacokinetics/Pharmacodynamics

Target Concentrations
The study of the pharmacodynamic effect of antiretrovirals in the CNS is complicated by the absence of a clear target. The optimal marker would be the inhibition of HIV tissue replication in the whole brain parenchyma: such a marker is currently not feasible.
The use of CSF HIV RNA as a marker of antiviral activity is the most commonly used one since it decreases with the introduction of HAART and it parallels cognitive improvement in patients with HAD [124] [125] [126] [127] . Nevertheless, commercial kits for measuring HIV RNA have not been validated in the CSF and the optimal threshold is currently unknown. Second-generation methods can quantify as low as 20 copies/mL; very sensitive experimental techniques (quantifying 2 copies/mL) have been assessed and residual viraemia (between 2 and 50 copies/mL) was associated with worse cognitive function [128, 129] . The measurement of other CSF markers (such as neopterine or CCL2) may be useful for understanding the pathogenesis of neuronal damage and, potentially, for monitoring changes in immune activation or neuronal function, but it is still not used except for research purposes [3, 130] .
The use of magnetic resonance spectroscopy (MRS) and PET has the potential to describe neuronal integrity in different areas of the CNS and have successfully been used to describe antiretroviral effect: nevertheless, these techniques are expensive, time-consuming and not standardised [131] . A recent study using a selective ligand for the translocator protein expressed by activated microglial cells ([11C]-PK11195) showed that HIV-infected patients with long-standing virological suppression on combination antiretroviral therapy and without co-morbidities or drug and alcohol misuse had focal areas of activated microglial cells, indicative of neuroinflammation, in several cortical regions [132] .
Finally, one possibility would be to monitor cognitive function after the introduction of antiretrovirals: most studies reported an improvement after antiretroviral treatment initiation or modification [133] . Nevertheless, complete neurocognitive testing is time-consuming and may be influenced by the choice of the control group and by learning effect (patients repeating slightly modified tests may perform better) [28, 134] .
Given the inaccessibility of in vivo brain tissue, CSF inhibitory concentrations (IC 50 , IC 90 and IC 95 ) have been used to compare the adequacy of antiretrovirals exposure: these concentrations represents the level at which 50, 90 or 95 % of in vitro viral replication is inhibited (using wildtype viruses). However, these in vitro protein-free concentrations have significantly variable values and the same drug has been judged to reach optimal or insufficient concentrations in different studies when compared with different thresholds [49, 51, 123] . A recent study has quantified both protein-free and protein-corrected inhibitory concentrations of several antiretrovirals using a standardised methodology; [135] our group recently reported better CSF viral control (as CSF HIV RNA below 50 copies/mL and a lower prevalence of CSF escape) when drugs showed higher 95 % inhibitory quotients (as CSF exposure divided by IC95, derived by the aforementioned study) [136] .
Cerebrospinal Fluid Escape
In the majority of patients, CSF HIV RNA is lower than plasma HIV RNA (approximately 1 Log 10 ): higher CSF viral loads have been associated with active neurological symptoms and with a shorter time to develop HAND [137] . In some patients, despite plasma viral control CSF HIV RNA may be detectable or 1 Log 10 higher: this condition has been defined as 'CSF escape'. The exact clinical relevance of CSF escape is currently unknown since it may occur in approximately 10 % of patients on HAART and no neurological impairment was observed in a longitudinal study after 5 years of follow-up: this event may therefore be similar to the emergence of plasma 'blips' [21, 138] . However, two case series and several case reports have clearly documented the concrete, though uncommon, possibility of symptomatic CSF escape: severe neurological syndromes and neuroradiological findings have been documented [22, 23, [139] [140] [141] [142] . In most of the subjects differential viral evolution (with resistance-associated mutation selected in the CSF compartment) was shown and it was explained by asymmetrical penetration of antiretrovirals (with some CSF concentrations below the limit of detection), but this was not confirmed by other reports [143] . In a large longitudinal study factors associated with CSF escape were the presence of CSF pleocytosis, the use of a PI-containing HAART and an ultrasensitive plasma HIV RNA level: [144] the poor CSF to plasma ratios observed with PIs (0-1.4 % with currently used PIs) may possibly explain these results as well as persistent intrathecal immune activation and plasma residual viraemia. In symptomatic patients, switching HAART to more neuroeffective drugs has been shown to improve symptoms and to reduce CSF viral load, and it appears advisable.
Efficacy of Monotherapy Versus Combination Antiretroviral Treatment
Pharmacodynamic data are available for a few compounds: patients received monotherapy and CSF HIV RNA decay was monitored. While lopinavir/ritonavir and zidovudine had a significant effect on CSF replication, didanosine and saquinavir showed no relevant effect [112, 145] . Abacavir was tested as an adjunctive therapy in patients with HAD: neurocognitive performance and CSF HIV RNA showed no significant change [86] . PI monotherapies have been tested given the need for reducing long-term toxicities and drug expenditure: this strategy is less effective than triple therapy but it is efficacious in the majority of patients.
Concerns have been raised on the compartmental activity of low penetrating drugs such as PIs: data on several neurocognitive tests and a review of available data were reassuring on the effect of such strategies [146] [147] [148] [149] .
Nevertheless, a few patients on darunavir/ritonavir (two from the MONOI study) or lopinavir/ritonavir and several subjects on atazanavir/ritonavir as single agents presented neurological symptoms and elevated CSF HIV RNA despite plasma viral control [three of 20 in the ATAR-ITMO (Atazanavir-Ritonavir Monomaintenance) study with atazanavir] [150, 151] . Furthermore, even in patients with controlled CSF HIV RNA, S100beta (a marker of astrocyte damage) rapidly increased after the interruption of NRTIs [152] . Combination antiretroviral treatment is usually effective in the CNS compartment and a rapid decay in CSF HIV RNA is observed; however, in some cases viral decay in the CSF and blood may differ. Slower decay of CSF HIV RNA has been noted in subjects with HAD and lower CD4 cell counts [125, 126, 153] . Ninety percent of patients with undetectable plasma HIV RNA presented CSF HIV RNA below 50 copies/mL: nevertheless, a compartmental residual viraemia was measurable through sensitive methods. CSF low-level viraemia was associated with neurocognitive impairment and increased immune activation and was unresponsive to intensification strategies (with maraviroc, enfuvirtide or raltegravir) [128, 129, 154, 155] .
The CNS Penetration-Effectiveness Score
The CNS Penetration-Effectiveness (CPE) score has been proposed by a large collaborative study group in the USA (the CHARTER group): [156] in the revised 2010 version antiretrovirals were scored 1-4 (where 4 is the most neuroeffective drug) according to drug characteristics, pharmacokinetic and pharmacodynamic properties [157] . The composite CPE (obtained by adding single drug scores to obtain a treatment score) has been used in several studies, leading to conflicting results. Most of the studies found a lower CSF HIV RNA with a higher CPE score, while the effect on immune activation, magnetic resonance imaging cerebral metabolite concentrations and neurocognitive testing were less concordant among studies: the results are summarised in Table 2 [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] . Furthermore, while several retrospective studies found an association between higher CPE scores and lower CSF viral loads [125, 152, [171] [172] [173] , only one study (of three) found a correlation with CSF escape [21, 143, 174] . Some reports tried to define a CPE cut-off: a value of 6 or 7 was found to be associated with heterogeneous CSF outcomes [143, 144, 171, 175] .
Some limitations of the CPE score must be highlighted: the limited amount of evidence regarding pharmacodynamic data and standard dosages of drugs, the absence of a clear cut-off, and its validation only in patients receiving triple therapies and with fully sensitive viruses. As an example, a CPE corrected for plasma resistance-associated mutations was a better predictor (compared with standard CPE) of HAND in a cross-sectional study [176] . For these reasons, some authors (and the Italian guidelines) prefer not to use the aggregate CPE, but they suggest that treatment optimisation in patients with CNS diseases may include drugs with an individual elevated neuro-effective score [172, 177] .
The CPE score is therefore a valuable and easy to use tool to implement the use of neuro-active drugs, although with some limitations. Nevertheless, a recent review using rigorous methods found that neuroHAART was effective in improving neurocognitive function and decreasing CSF viral load (although only two of those studies were adequately statistically powered): this confirms the possible optimisation of CNS treatment and calls for prospective, randomised, adequately powered studies [178] . A very interesting study (randomised and controlled) was conducted by Ellis et al. [169] but unfortunately it was prematurely interrupted for slow accrual (326 patients screened and 59 enrolled): CNS-targeted HAART was associated with neither virological nor neurocognitive improvements, although in patients with baseline suppressed viral load a trend for improved cognitive performances over time was observed.
Efficacy in Monocytes, Macrophages and Astrocytes
Given the peculiarity of infected cells in the CNS and several in vitro data, an increasing interest has arisen in antiretroviral activity on monocytes, macrophages and astrocytes. In vitro data suggest that the endogenous nucleoside pool in resting macrophages is smaller than that in activated lymphocytes and therefore that the effective phosphorylated NRTI concentrations required to inhibit HIV replication may be lower [179] . Shikuma et al. [180] used the in vitro effective concentration in acutely infected macrophages (EC 50 ) to calculate a 'monocyte efficacy score' (1/EC 50 9 1,000): surprising results were observed, with tenofovir being 17 times more efficacious than abacavir (50 vs. 3) . In 139 patients the composite score was nicely associated with neurocognitive performance and with the presence of HAND or a minor motor cognitive disorder. Recent data challenging infected astrocytes with several NRTIs, NNRTIs and raltegravir reported that some drugs (zidovudine, lamivudine and stavudine) may have inadequate inhibitory activity in astrocytes, with the EC 90 values exceeding those achievable in the CSF [181] . These preliminary observations warrant further studies on the differential efficacy of antiretrovirals according to target cells: the repeated association between HIV reservoir size (measured as peripheral blood mononuclear cell-or monocyte-associated quantitative HIV DNA) and HAND support the implementation of specific drug strategies in selected patients (for instance, those with low CD4? cells nadir, high HIV RNA zenith and high cumulative viraemia) [182, 183] .
Potential Adjunctive Effect of Maraviroc in the CNS
Maraviroc is a CCR5 antagonist that binds to the human co-receptor, thus preventing the stable interaction between R5-tropic HIV and target cells: the mechanism of action is therefore peculiar since it blocks an endogenous receptor and has an extracellular target. The compound has been associated with some immunological benefits such as a higher CD4 increase and, although less than expected, reduced immune activation in patients with poor immunological recovery [184] . The drug, used in combination with other antiretrovirals, has been proven to be effective in blocking HIV entry both in naïve and experienced patients. CNS target cells usually express CCR5 and most of the viruses are R5 tropic in the CSF (even if patients harbour X4-tropic viruses); discordant tropism (X4 in CSF samples and R5 in plasma) has been rarely reported, thus suggesting that maraviroc may be effective in treating CNS HIV infection in most patients [185] . While being CNS protective as monotherapy in a macaques model and suppressing CSF HIV RNA in patients with neurological symptoms, three studies evaluated the effects of maraviroc intensification. In one, it was not associated with the control of CSF residual viraemia despite good compartmental penetration [154] . After 14 days of treatment intensification small increases in cerebral metabolite markers of neuronal integrity (N-acetylaspartate/creatine ratios) were observed and they were associated with maraviroc plasma exposure; concomitantly higher plasma concentrations were associated with lower CSF CXCL10 (IP-10), an inflammatory chemokine, concentrations [186, 187] . Both for its activity in CNS target cells and for its non-antiviral properties, maraviroc treatment (either as switch or as intensification) may be an option in neurologically impaired HIV-positive patients with suppressed plasma viral load.
Antiretrovial Toxicity in the CNS
It must be highlighted that most antiretrovirals have a welldescribed toxicity in the peripheral nervous system while little is known on their toxicity profile in CNS neurons. Some in vitro data (immortalised cell lines and peripheral dorsal root ganglia neurons) showed the potential for antiretrovirals to produce neuronal damage: using primary cultures of rat forebrain, Robertson et al. [188] [189] [190] showed that several antiretrovirals achieved toxic concentrations in the CSF without any additive effect. Recent data further explored this hypothesis and the production of reactive oxygen species was confirmed in pigtail macaques and rats in vivo (with the exposure to zidovudine, saquinavir and ritonavir) [191] .
PIs and efavirenz have been associated with glucose and metabolic disturbances eventually leading to dyslipidaemia, glucose intolerance and abnormal fat distribution (lipodystrophy); the cumulative exposure to PIs has further being implicated in the increasing cardiovascular events observed in HIV-positive patients [192] . Previous studies suggest that HIV-infected patients are at increased risk of ischaemic cerebrovascular disease, potentially caused by infective vasculitis, brain opportunistic diseases, cardiac embolism, hypercoagulopathy or HIV infection itself [193, 194] . Among a variety of brain vessel diseases, cerebral small vessel disease (CVSD) has been associated with ischaemic stroke during life and cerebral infarction at autopsy. Recently, it was demonstrated that mild and moderate/severe small vessel diseases were associated with PI-based HAART exposure and that HAND was associated with mild CSVD (after adjusting for vessel mineralisation, HIV encephalitis, microglial nodular lesions, white matter lesions or older age) [195] . Further to this potentially relevant effect on cerebrovascular disease, PI-based combination treatment has been associated with reduced amyloid phagocytosis and increased neuronal accumulation, justifying some of the shared clinical features with Alzheimer's dementia [196, 197] .
Efavirenz effects in the CNS are well-characterised (abnormal dreams, dizziness) and associated with higher plasma concentrations and to SNPs in genes encoding for proteins involved in the drug metabolism or transport. Furthermore, being on efavirenz treatment was independently associated with the diagnosis of HAND in a cohort of stable HIV-positive patients [198] . One recent study reported that cognition improved for up to 96 weeks in a group of immunologically and virologically stable patients who elected to come off treatment; the improvement was significant in all participants but greater in efavirenz recipients [133] .
These results raise the possibility that antiretroviral concentrations may to some extent have detrimental effects: this may be particularly relevant for individuals with specific genetic profiles but it must be compared with the clear beneficial effect of HAART on compartmentalised viral control.
Conclusions
HAART is very effective in controlling HIV replication and in increasing patients' immune systems, thus preventing opportunistic diseases. In the CNS the same rule applies, although persistent immune activation have been demonstrated despite antiviral efficacy. Antiretroviral penetration into the CNS may depend on several drug and patient characteristics: the use of more neuro-effective drugs (high penetration and compartmental activity) has been associated with better CSF viral control and in some, but not all, studies with better neurocognitive performances. Antiretroviral regimens based on neuro-effective drugs may be suggested in patients with increased pharmacological needs (CSF escape, CNS compartmentalised viruses, high intrathecal immune activation) and neurocognitive disorders. The use of antiretroviral drugs with increased CSF penetration and/or effectiveness in treating or preventing neurocognitive disorders however needs to be assessed in well-designed prospective studies addressing antiretroviral neurotoxicity.
